- Home
- AKRO
as 11-04-2025 10:41am EST
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Upcoming Earnings Alert:
Get ready for potential market movements as Akero Therapeutics Inc. AKRO prepares to release earnings report on 07 Nov 2025.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 3.7B | IPO Year: | 2019 |
| Target Price: | $73.56 | AVG Volume (30 days): | 4.1M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.34 - $58.40 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Akero Therapeutics Inc. (AKRO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cheng Andrew | AKRO | President and CEO | Oct 10 '25 | Sell | $53.98 | 30,000 | $1,619,340.00 | 526,114 | |
| Rolph Timothy | AKRO | Chief Scientific Officer | Oct 7 '25 | Sell | $46.42 | 12,500 | $576,001.43 | 166,571 | |
| Young Jonathan | AKRO | Chief Operating Officer | Oct 1 '25 | Sell | $47.81 | 12,500 | $596,978.34 | 201,099 | |
| Rolph Timothy | AKRO | Chief Scientific Officer | Sep 8 '25 | Sell | $44.52 | 12,500 | $552,136.50 | 166,571 | |
| Young Jonathan | AKRO | Chief Operating Officer | Sep 2 '25 | Sell | $46.83 | 12,500 | $576,035.08 | 201,099 | |
| Young Jonathan | AKRO | Chief Operating Officer | Aug 12 '25 | Sell | $48.02 | 12,500 | $597,325.95 | 201,099 | |
| Henderson Jane | AKRO | N/A | Aug 12 '25 | Sell | $47.46 | 3,000 | $142,371.00 | 9,398 | |
| Cheng Andrew | AKRO | President and CEO | Aug 11 '25 | Sell | $48.79 | 30,000 | $1,457,595.98 | 526,114 |
Latest Akero Therapeutics Inc. News
AKRO Breaking Stock News: Dive into AKRO Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
Simply Wall St.
16 days ago
Assessing Akero Therapeutics (AKRO) Valuation After Strong Share Price Gains
Zacks
a month ago
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
Zacks
a month ago
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
Zacks
a month ago
5 Biotech Stocks Worth Adding to Your Portfolio Now
Zacks
2 months ago
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
MT Newswires
4 months ago
Akero Therapeutics Insider Sold Shares Worth $542,306, According to a Recent SEC Filing
MT Newswires
5 months ago
Akero Therapeutics Insider Sold Shares Worth $2,044,940, According to a Recent SEC Filing
Compare AKRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKRO Akero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.